BioCryst Pharmaceuticals, Inc. (BCRX)
9.92
+0.22
(+2.27%)
USD |
NASDAQ |
Sep 01, 16:00
9.92
0.00 (0.00%)
After-Hours: 17:23
BioCryst Pharmaceuticals Total Long Term Debt (Quarterly) : 834.73M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 834.73M |
| March 31, 2026 | 856.22M |
| December 31, 2025 | 477.01M |
| September 30, 2025 | 682.76M |
| June 30, 2025 | 738.52M |
| March 31, 2025 | 828.22M |
| December 31, 2024 | 840.48M |
| September 30, 2024 | 841.09M |
| June 30, 2024 | 849.62M |
| March 31, 2024 | 851.80M |
| December 31, 2023 | 847.66M |
| September 30, 2023 | 843.15M |
| June 30, 2023 | 825.10M |
| March 31, 2023 | 752.87M |
| December 31, 2022 | 739.08M |
| September 30, 2022 | 719.62M |
| June 30, 2022 | 628.38M |
| March 31, 2022 | 610.92M |
| December 31, 2021 | 591.42M |
| September 30, 2021 | 279.20M |
| June 30, 2021 | 267.76M |
| March 31, 2021 | 258.22M |
| December 31, 2020 | 123.61M |
| September 30, 2020 | 49.96M |
| June 30, 2020 | 54.60M |
| Date | Value |
|---|---|
| March 31, 2020 | 54.27M |
| December 31, 2019 | 53.72M |
| September 30, 2019 | 53.62M |
| June 30, 2019 | 53.59M |
| March 31, 2019 | 53.50M |
| December 31, 2018 | 32.70M |
| September 30, 2018 | 32.68M |
| June 30, 2018 | 22.79M |
| March 31, 2018 | 24.42M |
| December 31, 2017 | 54.72M |
| September 30, 2017 | 25.95M |
| June 30, 2017 | 25.70M |
| March 31, 2017 | 25.59M |
| December 31, 2016 | 53.72M |
| September 30, 2016 | 53.47M |
| June 30, 2016 | 30.61M |
| March 31, 2016 | 30.42M |
| December 31, 2015 | 32.38M |
| September 30, 2015 | 30.00M |
| June 30, 2015 | 30.00M |
| March 31, 2015 | 30.00M |
| December 31, 2014 | 30.00M |
| September 30, 2014 | 30.00M |
| June 30, 2014 | 30.00M |
| March 31, 2014 | 30.00M |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Amgen, Inc. | 57.30B |
| Vertex Pharmaceuticals, Inc. | 1.978B |
| Agenus, Inc. | 259.00M |
| Anika Therapeutics, Inc. | 23.32M |
| Imunon, Inc. | 5.914M |